Genomic Analysis of Pediatric Bone Tumors

Bone Cancer Clinical Trial

Official title:

Genomic Analysis of Pediatric Bone Tumors (Other Title: Pediatric Bone Tumor Biology Study)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01047878
• Other study ID #: PEDSSARC0001
• Secondary ID: 97630SU-12082009
• Status: Completed
• Start date: August 2007
• Est. completion date: December 2019

Study information

• Verified date: July 2020
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To determine whether gene expression analysis of primary tumor samples before and after chemotherapy are predictive of long-term survival in pediatric patients with bone sarcomas (Ewings sarcoma (ES) and Osteosarcoma(OS)).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 163
• Est. completion date: December 2019
• Est. primary completion date: June 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 18 Years

Eligibility

Inclusion Criteria:All patients with bone x-rays suggestive of a malignant bone tumor Exclusion Criteria:Patients with a known diagnosis of cancer.

Related Conditions & MeSH terms

• Bone Cancer
• Bone Neoplasms

Locations

Country	Name	City	State
United States	Stanford University School of Medicine	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	% necrosis post chemotherapy		his is measured at the time of sample collection since we are looking for % necrosis in the sample we are collecting
Primary	overall survival and event free survival		This is measured at the time the patient dies, or at the time when patient relapses from their disease. There is no set time since this outcome is individually assessed.